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Abstract
Background: High-resolution magic angle proton magnetic resonance spectroscopy (HR 1H MAS MRS)
provides a broad metabolic mapping of intact tumor samples and allows for microscopy investigations of
the samples after spectra acquisition. Experimental studies have suggested that the method can be used
for detection of apoptosis, but this has not been investigated in a clinical setting so far. We have explored
this hypothesis in cervical cancers by searching for metabolites associated with apoptosis that were not
influenced by other histopathological parameters like tumor load and tumor cell density.
Methods: Biopsies (n = 44) taken before and during radiotherapy in 23 patients were subjected to HR
MAS MRS. A standard pulse-acquire spectrum provided information about lipids, and a spin-echo spectrum
enabled detection of non-lipid metabolites in the lipid region of the spectra. Apoptotic cell density, tumor
cell fraction, and tumor cell density were determined by histopathological analysis after spectra acquisition.
Results: The apoptotic cell density correlated with the standard pulse-acquire spectra (p < 0.001), but
not with the spin-echo spectra, showing that the lipid metabolites were most important. The combined
information of all lipids contributed to the correlation, with a major contribution from the ratio of fatty
acid -CH2 to CH3 (p = 0.02). In contrast, the spin-echo spectra contained the main information on tumor
cell fraction and tumor cell density (p < 0.001), for which cholines, creatine, taurine, glucose, and lactate
were most important. Significant correlations were found between tumor cell fraction and glucose
concentration (p = 0.001) and between tumor cell density and glycerophosphocholine (GPC)
concentration (p = 0.024) and ratio of GPC to choline (p < 0.001).
Conclusion: Our findings indicate that the apoptotic activity of cervical cancers can be assessed from the
lipid metabolites in HR MAS MR spectra and that the HR MAS data may reveal novel information on the
metabolic changes characteristic of apoptosis. These changes differed from those associated with tumor
load and tumor cell density, suggesting an application of the method to explore the role of apoptosis in
the course of the disease.
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Apoptosis plays an important role in cancer development,
progression, and response to therapy [1,2]. Malignant
cells have defects in cellular death pathways and therefore
the ability to circumvent apoptosis and survive under
abnormal conditions [3]. Low apoptotic activity has been
associated with aggressiveness and treatment resistance of
many tumor types, including cervical carcinomas [4,5].
Apoptosis is also an important mode of cell death after
chemo- and radiotherapy, although its relative contribu-
tion to the overall cell death has not been clarified [2].
Information on the apoptotic activity in tumors and the
metabolic changes involved may give valuable insight
into the mechanisms underlying cancer progression and
treatment response. Considerable effort is therefore put
into the development of clinically useful methods for
detection and exploration of apoptosis.
MR spectroscopy allows for a broad metabolic mapping of
tissues at the molecular level that may be used to investi-
gate the balance between cell death and survival [6].
Detailed biochemical characterization of hundreds of
metabolites is provided in a single experiment, yielding
specific information on the turnover of lipids, carbohy-
drates, and polypeptides [7]. Experimental studies, both
in vivo and based on tissue extracts, have indicated a
potential of the method to detect apoptosis from the lev-
els of cholines and fatty acids [8,9]. Recent developments
by utilization of the HR MAS technique have enabled pro-
duction of high quality spectra from intact tissues without
the artefacts introduced by extraction procedures [10].
Histological studies can be performed on the samples
after spectrum acquisition, yielding information on the
underlying causes of the metabolic data.
There is currently a large interest in exploring the clinical
potential of HR MAS MRS. Several studies have shown
that malignant lesions can be distinguished from benign
ones in the spectra [11-16], and utilizations of the method
for prediction of tumor aggressiveness and treatment out-
come have been proposed [12,14,15]. Only a few HR MAS
studies have investigated the relationship between apop-
tosis and spectral data [17-20]. The studies are based on
rat gliomas with high apoptotic activity and homogene-
ous tissue composition compared to human tumors. Nor-
mal cells within the tumor contribute significantly to the
MR signals and increase the complexity of clinical data.
The proportion of malignant cells and their apoptotic
activity may be interrelated, necessitating identification of
spectral characteristics of apoptosis that differ from those
associated with tumor load and tumor cell density. The
clinical relevance of the previous findings is therefore not
clear.
The present work was conducted to explore the utilization
of HR MAS MRS for detection of apoptosis in cervical can-
cers. Spectral characteristics specific for apoptotic cell den-
sity, tumor cell fraction, and tumor cell density, as
determined by histopathologic analysis of the samples
after spectrum acquisition, were searched for. Biopsies
taken before the start of treatment and after one week of
therapy were included to achieve a broad, but clinically
relevant, range of the histopathologic parameters. Signifi-
cant relationships between the HR MAS MR spectra and
the histopathology were found and metabolites specific
for apoptosis that were clearly distinguished from those
associated with tumor cell fraction and tumor cell density
were identified.
Methods
Patients and tumor samples
Twenty-three patients with primary squamous cell carci-
noma of the uterine cervix were included. Tumor stage
(The Fédération Internationale des Gynaecologistes et
Obstetristes) was 1b (1 patient), 2b (16), and 3b (6). All
patients were treated with curative intent. Radiotherapy
was given to all but one patient, who received surgery.
External irradiation, a total of 50 Gy to tumor and para-
metria and 45 Gy to the rest of the pelvic region, was given
in fractions of 2 and 1.8 Gy, respectively. Brachytherapy,
21 Gy in five fractions, was thereafter employed. Nineteen
patients received adjuvant cisplatin (40 mg/m2) weekly
during the period of external radiation, starting the same
day as the radiotherapy. The study was approved by the
local ethical committee, and written informed-consent
was obtained from all patients.
Tumor biopsies, 5 × 5 × 5 mm in size, were taken before
the start of treatment from all twenty-three patients and
after 1 week (10 Gy) of external radiotherapy from twenty
patients. Two pre-treatment biopsies were included for
one of the patients, leading to a total of 44 samples.
Efforts were made to select samples from the viable tumor
tissue, avoiding necrotic regions that were sometimes vis-
ible particularly after 1 week of therapy. The biopsies were
immediately frozen in liquid nitrogen and stored at -80°C
until MR analysis.
MR experiments
The samples were cut to fit a MAS rotor (50 µL, mean sam-
ple weight 16.2 mg), and added phosphate buffered
saline made up in D2O with trimethylsilyl propionic acid
(TSP, 1.4 mM) as a chemical shift reference and standard
for quantification of metabolites. HR MAS experiments
were performed on a Bruker Avance DRX600 spectrome-
ter equipped with a 1H/13C MAS probe with gradient
aligned with the magic angle axis (Bruker BioSpin GmbH,
Germany), as reported earlier [14]. Samples were spun at
5 kHz at an instrumental temperature setting of 4°C. TwoPage 2 of 12
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acquire spectrum with suppression of water signal (zgpr;
BRUKER) allowed for quantification of metabolite con-
centrations and provided information on lipid metabo-
lites, whereas a spin-echo spectrum with suppression of
both water and lipid signal (cpmgpr; BRUKER) enabled
detection of non-lipid metabolites in the spectral region
of the lipids. The standard pulse-acquire experiments
included a 60° flip angle over a spectral region of 20.0
ppm after 3.0 sec of water presaturation. The free induc-
tion decay (FID) was acquired into 64 K points during
2.72 sec, and 32 transients were collected. The spin-echo
experiments were performed using 2 sec of water suppres-
sion prior to a 90 degrees excitation pulse. A total of 128
transients over a spectral region of 16.7 ppm were col-
lected into 32 K points during 1.64 sec. The T2-filtering
was obtained using a delay of 1 ms repeated 136 times,
resulting in 285 ms effective echo time. The repetition
time was 3.93 sec. Spectral assignments were performed
based on our previous HR MAS study of cervical cancers
[13]. The samples were fixed in formalin after the MR
experiment. A time period of 30 min was used for spec-
trum acquisition, and the mean period from the start of
the experiment to fixation was 1 hour 55 min. The FIDs
were Fourier transformed after 0.3 Hz exponential line
broadening, and the phase was manually corrected. A lin-
ear baseline correction was applied. Chemical shifts were
referenced to the TSP peak at 0 ppm.
Histopathologic examinations
The samples were embedded in paraffin casts. A 5 µm
thick section from the middle part of each biopsy was sub-
jected to histological analysis for determination of apop-
totic cell density, tumor cell fraction, and tumor cell
density, as described previously [21], assuming that the
data of this section were representative for the entire
biopsy. One biopsy contained solely necrosis. Stroma and
tumor cells, but no necrosis, were seen in the others. Since
necrosis most often affects many adjacent cells at the same
time and is easily visible in the microscope, the propor-
tion of necrosis was assumed to be zero in the latter biop-
sies. In contrast, apoptosis may often occur in single cells
spread throughout the tissue.
To detect the apoptotic cells, the sections were stained by
use of the Apotag in situ apoptosis detection kit (Oncor,
Gaithersburg, MD), which is based on the terminal deox-
ynucleotidyl transferase (TdT)-mediated dUTP-biotin
nick end labeling (TUNEL) method. Slide preparation
and staining were performed as described by the manufac-
turer. A biopsy from a neoplastic lymph node of a patient
with B-cell non-Hodgkin's lymphoma served as a positive
control, whereas negative controls received no TdT. Apop-
totic cell density was defined as the number of apoptotic
tumor cells per mm2 of tissue (including stroma and
tumor tissue), and was calculated as:
At = Fc·Ac  (1)
where At is apoptotic cell density, Fc is tumor cell fraction,
and Ac is number of apoptotic nuclei per mm2 of tumor
tissue. Fc was determined in hematoxylin and eosin (HE)
stained sections by point counting at a magnification of
100×, and Ac was determined by counting all apoptotic
cells within the tumor tissue at high magnification
(400×).
Tumor cell density, defined as number of tumor cell
nuclei per mm2 of tissue (including stroma and tumor tis-
sue), was calculated as:
Dt = Fc·Dc (2)
where Dt is tumor cell density, Fc is tumor cell fraction,
and Dc is number of nuclei per mm2 of tumor tissue. Dc
was determined in HE stained sections by counting all
nuclei within selected fields in the tumor tissue at high
magnification (400×).
Apoptotic cell density, tumor cell fraction and tumor cell
density were also determined in nine samples that had not
been subjected to MR examinations. These data were com-
pared to the data of the HR MAS samples, to search for sys-
tematic changes in the histopathology caused by the MR
experiement. The samples were prepared and analysed as
described above.
Partial least square regression (PLS)
The MR spectra and histopathological parameters were
analysed by PLS to identify the metabolites that were most
strongly related to apoptotic cell density, tumor cell frac-
tion, and tumor cell density. The analysis relates varia-
tions in one or several dependent variables; i.e, the
histopathological parameters, to the variations of several
independent variables; i.e., the spectral data, with explan-
atory or predictive purposes. The method performs well
when the independent variables are collinear, which can
be expected with MR data. The information in the original
MR spectra was projected onto a number of principal
components (PCs). The histolopathological parameters
were actively used in estimating the PCs, ensuring that the
first PCs were those that were most relevant for predicting
the parameter.
The MR spectra were converted to ASCII-format, peak
aligned according to a recently reported algorithm
[22,23], and imported into the Unscrambler package
(CAMO process AS, Norway) for PLS analysis. The region
between 0.7 and 2.2 ppm, mainly containing broad reso-Page 3 of 12
(page number not for citation purposes)
BMC Cancer 2007, 7:11 http://www.biomedcentral.com/1471-2407/7/11nances from lipids with signals from the fatty acid protons
- CH3 (0.9 ppm), - (CH2)n (1.3 ppm), - CH2 - CH3 (1.35
ppm), - CH2 - CH2 - CO (1.58 ppm), - CH = CH - CH2 -
CH2 (2.02 ppm), was used in the standard spectra. The
ethanol triplet at 1.19 ppm that occurred due to the labo-
ratory sterilizing procedure, was excluded. In the spin-
echo spectra the regions containing the peaks for glucose,
lactate, myo-inositol, taurine, glycerophosphocholine
(GPC), phosphocholine (PC) choline, and creatine were
selected for further analysis. Baseline offset was adjusted,
and the spectra were scaled by mean normalisation; i.e.,
the area below the curve was made equal for all spectra.
PLS calibration of apoptotic cell density, tumor cell frac-
tion, and tumor cell density to the spectral variables was
performed in separate runs. The model calibrations were
performed with mean centered data; i.e., the average of
each variable subtracted from each of the data values in
the variable. This centering means that the results can be
interpreted in terms of deviations from the average. Full
cross-validation (leave-one-out) was applied in model
calibration. The number of PCs to retain in the model was
determined by finding the principal component where
total residual y-variance and root mean square error of
prediction were minimised. Loading profiles of the prin-
cipal components were generated to visualize the relative
contribution of the metabolites to the model. Pearson
correlation analysis was used to find the correlation
between the predicted and measured parameter.
Estimation of metabolite concentrations
To further explore the association between metabolites
and histopathology, correlation analyses based on indi-
vidual metabolite concentrations and metabolite ratios
were performed. The concentrations were calculated for β-
glucose, GPC, PC, choline, creatine, lactate, fatty acid -
CH2 (1.3 ppm), fatty acid -CH3 (0.9 ppm), and TSP from
the standard pulse-acquire spectra, as described previ-
ously [14]. The spectral regions 4.6 to 4.7 ppm (β-glu-
cose), 3.4 to 2.9 ppm (GPC, PC, choline, and creatine),
1.8 to 0.5 ppm (lipids and lactate), and -0.1 to 0.1 ppm
(TSP) were individually baseline corrected, using a linear
function. Peak areas were calculated using combined
Lorentzian and Gaussian line functions (Voigt area) in a
curve-fitting program (PeakFit, Systat Software Inc., Rich-
mond, CA). The correlation coefficient, r, of the fit was
0.95 or larger for all area calculations. The peak area of the
metabolite relative to the area of the internal standard TSP
and sample wet weight was used as a measure of metabo-
lite concentration. The concentrations were related to the
histopathological parameters by use of Pearson correla-
tion analysis and the SPSS software.
Results
Histopathology and spectral characteristics
The histolopathology differed considerably among the
samples. To avoid confounding effects due to the influ-
ence of necrosis on the spectra, the necrotic sample was
not included in the statistical analyses but was handled
separately. Apoptotic cell density, tumor cell fraction, and
tumor cell density of the other samples ranged from 0 –
189 apoptotic cells per mm2 (median 16 apoptotic cells
per mm2), 8 – 100% (median 51%), and 214 – 11542
cells per mm2 (median 2357 cells per mm2), respectively.
Apoptotic cell density was generally higher whereas tumor
cell fraction and tumor cell density were lower in the
biopsies taken during therapy compared to the pretreat-
ment ones from the same tumor, reflecting treatment
induced apoptosis and cell death. However, when biop-
sies from different tumors were compared, no such trend
was observed. Hence, many of the pretreatment biopsies
had more apoptosis and lower tumor cell fraction and
tumor cell density than biopsies taken during therapy
from other tumors. The morphology of the samples did
not change during the MR experiments, and there was no
increase in apoptotic cell density or decrease in tumor cell
density either (Figure 1).
All MR spectra were highly resolved and comparable to
our previous results for cervical cancers [13]. Broad reso-
nances from lipids and macromolecules, as well as sharp
peaks from smaller compounds, like lactate, amino acids,
and cholines, could be seen in the standard pulse-acquire
spectra, whereas amino acids, like alanine and valine,
were detected in the lipid region of the spin-echo spectra
in addition to the other compounds (Figure 2). Pro-
nounced differences were often observed between spectra
acquired from different biopsies, especially in the region
above 3.0 ppm, as demonstrated in Figures 2A and 2B.
The differences could be seen regardless of whether the
pre-treatment biopsies or all samples were compared.
They were therefore not a general effect of the treatment,
but reflected biological characteristics of the tissues.
Relationships between histopathology and spectral 
profiles
Apoptotic cell density showed a significant correlation to
the standard pulse-acquire spectra in PLS analysis (Figure
3). No association was found between the spin-echo spec-
tra and apoptotic cell density, suggesting that the lipid
region contained the main information on apoptosis. The
PLS model had eleven valid principal components, and a
single informative loading profile could therefore not be
generated. However, the highly apoptotic samples had
generally a high score of PC1 compared to the others (Fig-
ure 3A). A strong correlation was found between the pre-
dicted and measured apoptotic cell density (r = 0.95, p <
0.001) (Figure 3B), indicating that the apoptotic cell den-Page 4 of 12
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correlation coefficient was partly caused by two highly
apoptotic samples. However, the relationship was signifi-
cant even when these samples were excluded (r = 0.53, p
< 0.001), showing that the result did not rely on them
alone.
In contrast to the apoptotic cell density, the tumor cell
fraction showed a strong association to the spin-echo
spectral profile (Figure 4), whereas the relationship to the
standard pulse-acquire spectra was weaker (data not
shown). Two principal components were retained in the
model, and samples with high tumor cell fraction had
high score values for the first principal component (PC1)
compared to those with low tumor cell fraction (Figure
4A). The former samples were associated with increased
levels of lactate, creatine, GPC, and PC and lower levels of
glucose, myo-inositol, taurine, and choline, as could be
seen from the loading profile of PC1 (Figure 4B). There
was a highly significant correlation between the predicted
and measured tumor cell fraction (r = 0.81, p < 0.001)
(Figure 4C).
PLS analysis of tumor cell density showed similar results
as for tumor cell fraction, a strong association to the spin-
echo spectral profile (Figure 5), whereas the relationship
to the standard spectra was weaker (data not shown). The
model consisted of three principal components, and sam-
Apoptotic cell density (A) and tumor cell density (B) in cervical cancer biopsies after HR MAS MR spectroscopy versus the cor-responding data of samples from the same tumors but not subjected to MR spectroscopyFigure 1
Apoptotic cell density (A) and tumor cell density (B) in cervical cancer biopsies after HR MAS MR spectroscopy versus the cor-
responding data of samples from the same tumors but not subjected to MR spectroscopy. MR spectroscopy was performed at 
an instrumental setting of 4°C. The HR MAS samples were fixed in formalin after spectrum acquisition, using an average time 
period of 1 hour 55 min from the start of the experiment to fixation. Each point represents the data of a single biopsy. The val-
ues were calculated as number of apoptotic tumor cells (A) and tumor cells (B) per mm2 of tumor tissue. Lines of unity are 
shown. Note that there was no increase in apoptotic cell density or decrease in tumor cell density caused by the MR experi-
ment. The increased tumor cell density (B) was probably due to a minor increase in the thickness of the histological sections 
from the HR MAS samples as compared to the others.
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BMC Cancer 2007, 7:11 http://www.biomedcentral.com/1471-2407/7/11ples with high tumor cell density had high score of PC1
compared to the other samples (Figure 5A). The metabo-
lites associated with a high PCI score and therefore a high
tumor cell density were the same as those associated with
a high tumor cell fraction, although high levels of GPC
and PC and low levels of choline seemed to be more dom-
inant and high levels of lactate were less important (Figure
5B). The correlation between the predicted and measured
tumor cell density was also comparable to that achieved
for tumor cell fraction (r = 0.80, p < 0.001) (Figure 5C).
Relationships between histopathology, metabolite 
concentrations, and metabolite ratios
Analysis of individual metabolites and metabolite ratios
against the histopathological parameters led to lower cor-
relation coefficients than found in the PLS analysis, how-
ever, significant correlations were found (Table 1).
Apoptotic cell density was the only one showing a signifi-
cant relationship to the ratio of fatty acid -CH2 to -CH3 (r
= 0.36; p = 0.018). Hence, apoptotic samples had a high
content of fatty acid - CH2 compared to fatty acid - CH3,
Histological section and HR MAS MR standard pulse-acquire spectrum (upper) and spin-echo spectrum (lower) of two cervical cancer b opsi s, e with no apoptosis (A) and another with significant a optotic activity (B)Figure 2
Histological section and HR MAS MR standard pulse-acquire spectrum (upper) and spin-echo spectrum (lower) of two cervical 
cancer biopsies, one with no apoptosis (A) and another with significant apoptotic activity (B). The histological sections were 
stained for apoptotic cells by use of the TUNEL method after spectrum acquisition. The biopsy presented in (A) had a tumor 
cell fraction of 85%, tumor cell density of 9552 cells/mm2, and no apoptosis, whereas the corresponding data of the biopsy in 
(B) were 35%, 3606 cells/mm2, and 8.3 apoptotic cells/mm2. Bars in the histological sections represent 50 µm, and arrows in 
(B) point to apoptotic cells. Note the highly preserved morphology of the samples after spectrum acquisition. Spectral assign-
ments are abbreviated: β-Glc, β-glucose; Lac, lactate; m-Ino, myo-inositol; Cre, creatine; Gly, glycine; Tau, taurine; s-Ino, scyllo-
inositol; GPC, glycerophosphocholine; PC, phosphocholine; Cho, choline; FA, fatty acids; TSP, trimethylsilyl propionic acid; 
Asp, aspartate; Gln, glutamine; Suc, succinate; Glu, glutamate; Ac, acetate; Ala, alanine; β-OH-but, β-hydroxybutyrate; Val, 
valine. The position of hydrogens in fatty acids giving rise to the different peaks is marked in bold after the notation FA in the 
upper spectra.
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Score plot of first principal component (PC1) versus second principal component (PC2) from partial least square (PLS) regres-sion calibration of apoptotic cell density to single-pul  spectral dat  (A), and the predicted versus measured apoptotic cell d n-ty (B)Figure 3
Score plot of first principal component (PC1) versus second principal component (PC2) from partial least square (PLS) regres-
sion calibration of apoptotic cell density to single-pulse spectral data (A), and the predicted versus measured apoptotic cell den-
sity (B). Each point represents the data of a single biopsy. In (A) the color code for apoptotic cell densities (cells/mm2) is 
shown. The Pearson correlation coefficient and p-value are marked in (B). Total residual y-variance and root mean square 
error of prediction were minimised by retaining 11 PCs in the model. These 11 PCs accounted for 98% of the total x-variation, 
and 92% of the total y-variation. An informative loading profile could not be generated due to the high number of principal 
components that were retained in the model.
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Score plot of first principal component (PC1) versus second principal component (PC2) from partial least square (PLS) regres-sion analysis of tumor ell fraction to spin-echo spectral data (A), the correspo ding loading profile of PC1 (B), and the pre-dicted ver us measu ed tumor cell fraction (C)Figure 4
Score plot of first principal component (PC1) versus second principal component (PC2) from partial least square (PLS) regres-
sion analysis of tumor cell fraction to spin-echo spectral data (A), the corresponding loading profile of PC1 (B), and the pre-
dicted versus measured tumor cell fraction (C). In (A) and (C) each point represents the data of a single biopsy. In (A) the color 
code for tumor cell fractions (%) is shown. Spectral assignments are abbreviated in (B): β-Glc, β-glucose; Lac, lactate; m-Ino, 
myo-inositol; Cre, creatine; Tau, taurine; GPC, glycerophosphocholine; PC, phosphocholine; Cho, choline. The Pearson corre-
lation coefficient and p-value are marked in (C). Total residual y-variance and root mean square error of prediction were min-
imised by retaining 2 PCs in the model. These two PCs accounted for 45% of the total x-variation, and 66% of the total y-
variation.
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Score plot of first principal component (PC1) versus second principal component (PC2) from partial least square (PLS) regres-
sion analysis of tumor cell density to spin-echo spectral data (A), the corresponding loading profile of PC1 (B), and the pre-
dicted versus measured tumor cell density (C). In (A) and (C) each point represents the data of a single biopsy. In (A) the color 
code for tumor cell densities (cells/mm2) is shown. Spectral assignments are abbreviated in (B): β-Glc, β-glucose; Lac, lactate; 
m-Ino, myo-inositol; Cre, creatine; Tau, taurine; GPC, glycerophosphocholine; PC, phosphocholine; Cho, choline. The Pearson 
correlation coefficient and p-value are marked in (C). Total residual y-variance and root mean square error of prediction were 
minimised by retaining 3 PCs in the model. These three PCs accounted for 52% of the total x-variation, and 65% of the total y-
variation.
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Apoptotic cell density was not related to any of the other
metabolites, in agreement with the PLS result showing
that the lipid region was most important. Tumor cell den-
sity showed a positive correlation to GPC concentration (r
= 0.35; p = 0.024) and an even stronger relationship to the
ratio of GPC to choline (r = 0.53; p < 0.001), whereas
tumor cell fraction was inversely correlated to glucose
concentration (r = -0.52; p = 0.001), consistent with the
PLS results. Of notice is that the necrotic sample had the
third highest fatty acid -CH2 to -CH3 ratio, and therefore a
characteristic similar to the highly apoptotic samples.
Moreover, GPC concentration and ratio of GPC to choline
were relatively low in this sample, resembling samples
with low tumor cell density.
Discussion
Detailed characterization of intact samples from cervical
carcinomas by use of HR MAS MRS enabled identification
of metabolites associated with apoptotic cell density,
tumor cell fraction, and tumor cell density in our study.
We showed that the samples were well preserved and that
no apoptosis or cell death was induced during spectrum
acquisition, in accordance with recent studies showing
stable expression of apoptosis promoting genes during
the experiment [18]. These findings justified direct corre-
lation studies between MR data and histopathology and
exploration of the underlying causes of the spectral pro-
files. Metabolites that were characteristic of apoptosis and
differed from those associated with tumor cell fraction
and tumor cell density were identified. The strongest rela-
tionship to the histopathology was achieved by including
the spectral profiles of several metabolites in the analyses,
showing that the combined metabolic information was
important.
Apoptotic cell density correlated with the standard pulse-
acquire spectra but not with the spin-echo profiles, sug-
gesting that the lipid region contained the major informa-
tion on apoptosis. In agreement with this hypothesis, the
ratio of fatty acid - CH2 to - CH3, but none of the choline-
containing metabolites, creatine, taurine, glucose, or lac-
tate, was associated with apoptosis when individual
metabolites and metabolite ratios were considered. Simi-
lar relationships between fatty acid -CH2 to -CH3 and
apoptosis have also been reported in MR spectroscopy
studies on Jurkat T-cell cultures treated with doxorubicin
[8]. A weaker correlation was, however, found in our
study probably because of the smaller range of apoptotic
cell densities. The elevated -CH2 to -CH3 ratio in highly
apoptotic tissues indicates increased fatty acid -CH2 chain
length and/or increased degree of fatty acid saturation as
apoptosis develops. The cause of this observation is not
known, both dynamic and/or compositional changes in
the plasma membrane and in cytoplasmic lipid droplets
have been proposed [6]. The fatty acid - CH2 to -CH3 ratio
was not significantly influenced by tumor cell fraction or
tumor cell density in our study, but reflected the apoptotic
activity per se, suggesting that this ratio can be used as an
independent measure of apoptosis in cervical carcinomas.
Spectral characteristics associated with tumor cell fraction
and tumor cell density were found in the region above 3
ppm. Choline, PC, and GPC were major metabolites con-
tributing to the correlation in both cases, as verified from
the loading profiles in the PLS analysis. High levels of
GPC and PC and low levels of choline indicate activation
of the phosphatidylcholine pathway and consequently a
high membrane turnover and/or activation of cell prolif-
eration and survival signalling [24,25], consistent with a
high tumor cell fraction or tumor cell density. Up-regula-
tion of the choline transport through the activation of
choline kinase, leading to the observed changes in the
choline metabolites, have been reported for many tumor
types and is thought to be a common feature of cancers
[26]. GPC concentration and GPC to choline ratio corre-
lated with the tumor cell density in analysis of individual
metabolites and ratios, whereas tumor cell fraction
showed no such correlation, probably reflecting the cellu-
lar rather than extracellular localization of these metabo-
lites and therefore a major dependence on the number of
cells in the sample. Choline-containing metabolites have
Table 1: Correlations between HR MAS MR metabolites and histopathology of cervical carcinomas
Apoptotic cell density Tumor cell fraction Tumor cell density
r1 p1 r p r p
Concentrations2
β-Glc NS -0.52 0.001 NS
GPC NS NS 0.35 0.024
Ratios
GPC/Cho NS NS 0.53 < 0.001
FA-CH2/FA-CH3 0.36 0.018 NS NS
1Correlation coefficients and p-values from Pearson correlation analysis. A threshold value of p = 0.05 was used for significance; NS means not 
significant.
2Spectral assignments are abbreviated β-Glc, β-glucose; GPC, glycerophosphocholine; Cho, choline; FA, fatty acid.Page 10 of 12
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liposarcomas from non-cancerous tissue in HR MAS spec-
tra [11-16]. Our results suggest a quantitative utilization
of these data to assess tumor cell density in cervical cancer
samples.
Creatine, taurine, glucose, and lactate also contributed to
the strong correlation between the spectral profiles and
tumor cell fraction and tumor cell density. Increased lev-
els of creatine and taurine have been observed in HR MAS
spectra of breast cancers as compared to non-malignant
tissue [14], consistent with our results. The mechanisms
underlying these findings have not been clarified, since
taurine appears to have different functions in different tis-
sues [27]. In contrast, the glucose and lactate data could
be explained from nutrient depletion and increased anaer-
obe metabolism in cervical tumors as compared to nor-
mal tissues [28,29]. The MR signals of these metabolites
originate from both the extracellular and cellular com-
partments [29], probably explaining the stronger relation-
ship to tumor cell fraction than to tumor cell density. We
have previously reported low glucose level in HR MAS
spectra of cervical carcinomas as compared to normal
samples [13]. Our present results indicate that this level
can be a quantitative marker of tumor cell fraction in the
carcinoma samples.
It was assumed that the spectral changes in lipid metabo-
lites were caused solely by apoptosis, and not necrosis, in
our work. Previous studies have shown that necrosis also
may lead to changes in these metabolites [30]. It cannot
be excluded that minor extent of necrosis was present in
the samples, although not detected in analyses, and influ-
enced the results. The only necrotic sample identified had
spectral characteristics that resembled the highly apop-
totic tissues with respect to lipid metabolites and tissues
with low tumor cell density with respect to GPC concen-
tration and ratio of GPC to choline. Further investiga-
tions, including both necrotic and apoptotic tissues, are
therefore needed to clarify whether the two modes of cell
death can be distinguished in the spectra or if the elevated
fatty acid -CH2 to -CH3 ratio can be used as a measure of
cell death in general.
Conclusion
Our studies showed that the apoptotic activity of cervical
carcinomas was associated with the lipid metabolites in
HR MAS MR spectra, whereas tumor cell fraction and
tumor cell density were related to cholines, creatine, tau-
rine, glucose, and lactate. This suggests that HR MAS MRS
may be used to explore the role of apoptosis in the course
of the malignant disease and to achieve increased insight
into the metabolic changes that occur during growth and
apoptosis development. The spectral information specific
of tumor load and tumor cell density allows for a more
complete picture of the sample histopathology that is
needed for a proper interpretation of the apoptosis data.
Our results also indicate that HR MAS MRS may be uti-
lized for monitoring of the therapeutic response of cervi-
cal carcinomas through the detection of treatment
induced cell death. The detailed information on changes
in apoptosis, tumor cell fraction, and tumor cell density
that can be achieved by metabolic mapping of biopsies
taken at different time points throughout the treatment
would be useful in judgement of the therapeutic effect.
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